Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TT-11X by Tessa Therapeutics for Lymphoproliferative Disorders: Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Lymphoproliferative Disorders. According to GlobalData, Phase...
TT-11X by Tessa Therapeutics for Leiomyosarcoma: Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase I...
TT-11X by Tessa Therapeutics for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL). According...
TT-11X by Tessa Therapeutics for Nasopharyngeal Cancer: Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase...
TT-11X by Tessa Therapeutics for Natural Killer Cell Lymphomas: Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Natural Killer Cell Lymphomas. According to...
TT-11X by Tessa Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
TT-11X by Tessa Therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
TT-11X by Tessa Therapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
TT-11X is under clinical development by Tessa Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to...